Austin Gurney - See Remarks, Oncomed Pharmaceuticals Inc

As of December 26, 2018


Austin Gurney Net Worth

  • Net worth is estimated to be at least $1.95M
  • Owns at least 66,807 units of Oncomed Pharmaceuticals Inc stock
  • Sold an estimated value of $1.78M in the last 5 years at Oncomed Pharmaceuticals Inc

Austin Gurney Compensation at Oncomed Pharmaceuticals Inc in 2017

  • Earned a $365,612 salary
  • Rewarded $154,536 in stock value and options
  • Received a total compensation of $1,442,108

Austin Gurney Trading

  • Largest sale of shares was 14,000 units , worth over $292.36K on July 31, 2015
  • In total has made about 31 transactions over 5 years
  • Usually trades in October, with the busiest year in 2014
Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1

Austin Gurney Mailing Address

  • Mailing address is C/o Oncomed Pharmaceuticals, Inc. 800 Chesapeake Drive Redwood City CA 94063 CA

Oncomed Pharmaceuticals Inc Executive Compensation

Name
Year
Salary
Stock Awards
Option Awards
Other Earnings Plans or Compensations
Total
John A. Lewicki, Ph.D., 2017 $419,777 $192,925 $967,675 $167,911 $1,748,288
John A. Lewicki, Ph.D., 2016 $407,550 $141,750 - $146,718 $696,018
Paul Hastings, 2017 $551,127 $169,650 $1,857,110 $60,624 $2,638,511
Paul Hastings, 2016 $535,075 $158,760 - $264,862 $958,697
Sunil Patel, 2017 $406,117 $183,600 $939,700 $167,780 $1,697,197
Austin Gurney, Ph.D., 2017 $365,612 $154,536 $804,964 $116,996 $1,442,108
Alicia Hager, J.D., Ph.D., 2017 $347,619 $154,536 $804,964 $125,143 $1,432,262
No matching records found

Source: https://www.sec.gov/Archives/edgar/data/1302573/000156459018009577/omed-def14a_20180622.htm

Oncomed Pharmaceuticals Inc Insider Trading

  • The most recent transaction was 11,117 units sold on December 26, 2018 by Austin Gurney worth over $6.67K
  • In the last 5 years, insiders at Oncomed Pharmaceuticals Inc sold an estimated value of $14.76M and bought an estimated value of $23.88M
  • The most active traders are Austin Gurney, See Remarks,  John A Lewicki, President and CEO,  and Alicia J Hager, SVP and General Counsel
  • Insider trading is most common in June, with the busiest year in 2015

OncoMed Pharmaceuticals Inc Insider Trades

Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1